Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.
Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.
Kala Bio shares surged 63% premarket to 48 cents after announcing the launch of its first purpose-built AI agent for biotech in just 14 days through the rebranded Researgency.ai platform.
Oppenheimer starts coverage on Ocugen with an Outperform rating and $10 price target, highlighting its lead gene therapy OCU400 in Phase 3 for retinitis pigmentosa and big market potential by 2027.
MiNK Therapeutics announces a new collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, including up to $1.1 million in funding.
Morgan Stanley downgraded Grifols stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1.
